On the same day it announced its plans to merge with privately held antibiotics developer Melinta Therapeutics Inc., Cempra Inc. revealed that it has worked out a somewhat easier path for responding to a December complete response letter for its macrolide antibiotic candidate Solithera (solithromycin) – but questions remain about who would fund a safety study with an estimated cost of $75m.
Acting CEO David Zaccardelli said Cempra negotiated with US FDA "a smaller, more focused and efficient approach" to obtain the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?